Avrobio Analyst Ratings
Avrobio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2023 | 39.86% | Wells Fargo | $2.5 → $2 | Maintains | Overweight |
| 07/12/2023 | 39.86% | Wedbush | → $2 | Downgrades | Outperform → Neutral |
| 03/24/2023 | 249.65% | Mizuho | $6 → $5 | Maintains | Buy |
| 03/24/2023 | 319.58% | Needham | → $6 | Reiterates | → Buy |
| 12/08/2022 | 179.72% | BTIG | → $4 | Upgrades | Neutral → Buy |
| 05/17/2022 | 319.58% | Needham | $8 → $6 | Maintains | Buy |
| 05/11/2022 | 179.72% | Barclays | $6 → $4 | Maintains | Overweight |
| 01/06/2022 | 319.58% | Mizuho | $28 → $6 | Maintains | Buy |
| 01/05/2022 | 319.58% | Barclays | $22 → $6 | Maintains | Overweight |
| 01/05/2022 | 109.79% | Morgan Stanley | $7 → $3 | Maintains | Equal-Weight |
| 01/05/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 01/05/2022 | 459.44% | Needham | $28 → $8 | Maintains | Buy |
| 11/19/2021 | 389.51% | Morgan Stanley | $24 → $7 | Downgrades | Overweight → Equal-Weight |
| 10/12/2021 | 1648.25% | Morgan Stanley | $27 → $25 | Maintains | Overweight |
| 07/16/2021 | 1927.97% | Morgan Stanley | $31 → $29 | Maintains | Overweight |
| 06/15/2021 | 1508.39% | BTIG | → $23 | Initiates Coverage On | → Buy |
| 05/27/2021 | 1858.04% | Needham | → $28 | Maintains | Buy |
| 05/14/2021 | 2067.83% | Morgan Stanley | $34 → $31 | Maintains | Overweight |
| 05/03/2021 | 599.3% | SVB Leerink | $18 → $10 | Maintains | Market Perform |
| 03/09/2021 | 1508.39% | Barclays | → $23 | Initiates Coverage On | → Overweight |
| 03/02/2021 | 879.02% | Stifel | → $14 | Initiates Coverage On | → Hold |
| 11/11/2020 | 1788.11% | Berenberg | → $27 | Initiates Coverage On | → Buy |
| 10/13/2020 | 2277.62% | Morgan Stanley | $35 → $34 | Maintains | Overweight |
| 07/15/2020 | 2347.55% | Morgan Stanley | $37 → $35 | Maintains | Overweight |
| 03/31/2020 | 2487.41% | Morgan Stanley | $40 → $37 | Maintains | Overweight |
| 03/31/2020 | 809.09% | HC Wainwright & Co. | $35 → $13 | Downgrades | Buy → Neutral |
| 03/31/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 02/12/2020 | 2697.2% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 11/11/2019 | 2137.76% | Wedbush | $43 → $32 | Maintains | Outperform |
| 10/28/2019 | 2347.55% | Nomura | → $35 | Initiates Coverage On | → Buy |
| 06/27/2019 | 1858.04% | Mizuho | → $28 | Initiates Coverage On | → Buy |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 11/28/2018 | 1788.11% | Leerink Swann | → $27 | Initiates Coverage On | → Market Perform |
| 09/17/2018 | 3186.71% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 08/13/2018 | 2697.2% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 07/16/2018 | 2697.2% | Wells Fargo | → $40 | Initiates Coverage On | → Outperform |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 2557.34% | Wedbush | → $38 | Initiates Coverage On | → Outperform |
| 07/16/2018 | 2487.41% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 07/13/2023 | 39.86% | 富國銀行 | $2.5→$2 | 維護 | 超重 |
| 07/12/2023 | 39.86% | 韋德布什 | →$2 | 評級下調 | 跑贏→中性 |
| 03/24/2023 | 249.65% | 瑞穗 | $6→$5 | 維護 | 買 |
| 03/24/2023 | 319.58% | 李約瑟 | →$6 | 重申 | →購買 |
| 12/08/2022 | 179.72% | BTIG | →$4 | 升級 | 中性→購買 |
| 2022/05/17 | 319.58% | 李約瑟 | $8→$6 | 維護 | 買 |
| 2022年05月11日 | 179.72% | 巴克萊 | $6→$4 | 維護 | 超重 |
| 01/06/2022 | 319.58% | 瑞穗 | $28→$6 | 維護 | 買 |
| 01/05/2022 | 319.58% | 巴克萊 | $22→$6 | 維護 | 超重 |
| 01/05/2022 | 109.79% | 摩根士丹利 | $7→$3 | 維護 | 等重 |
| 01/05/2022 | - | BTIG | 評級下調 | 購買→中性 | |
| 01/05/2022 | 459.44% | 李約瑟 | $28→$8 | 維護 | 買 |
| 2021年11月19日 | 389.51% | 摩根士丹利 | $24→$7 | 評級下調 | 超重→等重 |
| 10/12/2021 | 1648.25% | 摩根士丹利 | $27→$25 | 維護 | 超重 |
| 07/16/2021 | 1927.97% | 摩根士丹利 | $31→$29 | 維護 | 超重 |
| 2021/06/15 | 1508.39% | BTIG | →$23 | 開始承保 | →購買 |
| 2021/05/27 | 1858.04% | 李約瑟 | →$28 | 維護 | 買 |
| 2021/05/14 | 2067.83% | 摩根士丹利 | $34→$31 | 維護 | 超重 |
| 05/03/2021 | 599.3% | SVB Leerink | $18→$10 | 維護 | 市場表現 |
| 03/09/2021 | 1508.39% | 巴克萊 | →$23 | 開始承保 | →超重 |
| 03/02/2021 | 879.02% | Stifel | →$14 | 開始承保 | →保留 |
| 11/11/2020 | 1788.11% | 貝倫伯格 | →$27 | 開始承保 | →購買 |
| 10/13/2020 | 2277.62% | 摩根士丹利 | $35→$34 | 維護 | 超重 |
| 07/15/2020 | 2347.55% | 摩根士丹利 | $37→$35 | 維護 | 超重 |
| 03/31/2020 | 2487.41% | 摩根士丹利 | $40→$37 | 維護 | 超重 |
| 03/31/2020 | 809.09% | HC Wainwright公司 | $35→$13 | 評級下調 | 購買→中性 |
| 03/31/2020 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 02/12/2020 | 2697.2% | 摩根士丹利 | $37→$40 | 維護 | 超重 |
| 2019年11月11日 | 2137.76% | 韋德布什 | $43→$32 | 維護 | 跑贏大盤 |
| 2019年10月28日 | 2347.55% | 野村 | →$35 | 開始承保 | →購買 |
| 2019年06月27日 | 1858.04% | 瑞穗 | →$28 | 開始承保 | →購買 |
| 2019年05月04日 | - | 詹尼·蒙哥馬利·斯科特 | 開始承保 | →購買 | |
| 2018年11月28日 | 1788.11% | 利林克·斯旺 | →$27 | 開始承保 | →市場表現 |
| 2018年09月17日 | 3186.71% | HC Wainwright公司 | →$47 | 開始承保 | →購買 |
| 2018年08月13日 | 2697.2% | 摩根士丹利 | $37→$40 | 維護 | 超重 |
| 2018年07月16日 | 2697.2% | 富國銀行 | →$40 | 開始承保 | →跑贏大盤 |
| 2018年07月16日 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2018年07月16日 | 2557.34% | 韋德布什 | →$38 | 開始承保 | →跑贏大盤 |
| 2018年07月16日 | 2487.41% | 摩根士丹利 | →$37 | 開始承保 | →超重 |
What is the target price for Avrobio (AVRO)?
Avrobio(Avro)的目標價是多少？
The latest price target for Avrobio (NASDAQ: AVRO) was reported by Wells Fargo on July 13, 2023. The analyst firm set a price target for $2.00 expecting AVRO to rise to within 12 months (a possible 39.86% upside). 5 analyst firms have reported ratings in the last year.
富國銀行於2023年7月13日報道了Avrobio(納斯達克：AVRO)的最新目標價。這家分析公司將目標價定為2.00美元，預計Avro將在12個月內上漲(可能上漲39.86%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Avrobio (AVRO)?
Avrobio(Avro)的最新分析師評級是多少？
The latest analyst rating for Avrobio (NASDAQ: AVRO) was provided by Wells Fargo, and Avrobio maintained their overweight rating.
富國銀行對Avrobio(納斯達克代碼：AVRO)的最新分析師評級維持其增持評級。
When is the next analyst rating going to be posted or updated for Avrobio (AVRO)?
Avrobio(Avro)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avrobio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avrobio was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Avrobio的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Avrobio的上一次評級是在2023年7月13日提交的，所以你應該預計下一次評級將在2024年7月13日左右的某個時候公佈。
Is the Analyst Rating Avrobio (AVRO) correct?
分析師對Avrobio(Avro)的評級正確嗎？
While ratings are subjective and will change, the latest Avrobio (AVRO) rating was a maintained with a price target of $2.50 to $2.00. The current price Avrobio (AVRO) is trading at is $1.43, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Avrobio(Avro)的最新評級保持不變，目標價在2.50美元至2.00美元之間。Avrobio(Avro)目前的交易價格為1.43美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。